Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Vistra Corp (VST) Price & Performance

CVS Health CorpTrade
Vistra CorpTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Vistra Corp — how do they compare? CVS Health Corp trades at $86.32 (market cap $112.29B), while Vistra Corp trades at $161.29 (market cap $52.41B). The key difference: CVS Health Corp is far larger — about 2.1× Vistra Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Vistra Corp for 32 Days on average.

CVSVST
Market Cap
$112.29B$52.41B
Volume
7,763,67611,278,074
Sector
HealthUtilities
52-Week High
$110.60$210.85
52-Week Low
$70.08$134.71
Typical Hold Time
83 Days32 Days
Enterprise Value
$174.64B$74.34B
Dividend Yield
3.03%0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.

CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.

Vistra Corp

Vistra Corp. (VST) trades at $160.84, down 3.53% over the past day, amid mixed quarterly earnings but strong analyst support. The stock shows a bullish technical trend with support at $152 and resistance at $164, while fundamentals reflect robust profitability with an 11.55% net income margin and 75.73% ROE. Recent developments include a $4.2 billion US loan to expand nuclear power output and a 20-year power supply agreement with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.

Outlook remains positive given Wall Street's consensus price target of $215.23, implying 34% upside, though risks include earnings volatility and high valuation multiples. Investment appeal hinges on execution of growth initiatives in nuclear and data center power markets, with institutional confidence underscored by Peter Thiel's significant stake.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS
100% Buy0% Sell
Avg holding period · 83 Days
VST
49% Buy51% Sell
Avg holding period · 32 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.

Read more on VST →